Skip to main content
. 2021 Mar 31;157(5):1–10. doi: 10.1001/jamadermatol.2021.0345

Figure 2. Risk of Any Cancer With Topical Calcineurin Inhibitor (TCI) Treatment and Nonactive Comparator in Cohort Studies.

Figure 2.

Relative risks (RRs) were calculated using random-effects inverse variance method. Marker size indicates weight; diamond size indicates heterogeneity. PIM indicates pimecrolimus; TAC, tacrolimus.